Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
calculation (if not (Q)SAR)
Remarks:
Migrated phrase: estimated by calculation
Adequacy of study:
key study
Study period:
2009
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Expert judgement is combined with the prediction of metabolism provided by the OECD QSAR Application Toolbox.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2009
Report date:
2009

Materials and methods

Objective of study:
toxicokinetics
Principles of method if other than guideline:
No guideline exists for this type of appraisal.
GLP compliance:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Bis(2-ethylhexyl) 2,2'-thiobisacetate
EC Number:
246-131-9
EC Name:
Bis(2-ethylhexyl) 2,2'-thiobisacetate
Cas Number:
24293-43-4
Molecular formula:
C20H38O4S
IUPAC Name:
2-ethylhexyl 2-({2-[(2-ethylhexyl)oxy]-2-oxoethyl}sulfanyl)acetate
Details on test material:
not applicable

Test animals

Species:
other: not applicable
Details on test animals or test system and environmental conditions:
not applicable

Administration / exposure

Route of administration:
other: oral and dermal route are considered
Details on exposure:
not applicable

Results and discussion

Toxicokinetic / pharmacokinetic studies

Details on absorption:
Oral absorption of Di-2-EHTDG is predicted to be high. The Danish QSAR database predicts an oral absorption of 100% following a dose of 1 mg.
The Danish QSAR database predicts a very low dermal absorption of 0.00003 mg/cm²/event.
Details on distribution in tissues:
The substance will be hydrolysed; the hydrolysis products are water soluble and are predicted to have no accumulation potential. They are expected to enter the urine shortly after systemic absorption.
Details on excretion:
The hydrolysis products of Di-2-EHTDG as well as the oxidised metabolites are soluble in water (TDGA : 317 g/L; 2-EH : 1 g/L, 2-ethylhexanoic acid : 1.1 g/L) and will be excreted rapidly via urine, either as such or as conjugates with glucuronic acid. Significant faecal excretion is not expected.

Metabolite characterisation studies

Metabolites identified:
not measured
Details on metabolites:
Di-2-EHTDG will undergo enzymatic and non-enzymatic ester hydrolysis. This is a stepwise process and mixed hydrolysis and oxidation products are likely to occur at least as intermediate metabolites.
The resulting molecules, TDGA and 2-EH, are soluble in water. Both substances can be further oxidised [R2S to R2S(=O)2; -CH2OH to -COOH]. Carboxylic acids can be subject to glucuronidation (mediated by UGT isozymes) prior to urinary excretion.

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): no bioaccumulation potential based on study results
Di-2-EHTDG is predicted to be bioavailable via the oral route but is very poorly absorbed via skin.
Di-2-EHTDG is expected to undergo stepwise hydrolysis of the two ester bonds yielding 2,2'-thiodiglycolic acid and 2-ethylhexan-1-ol. Both substances are very polar and thus subject to renal elimination. Concomitant oxidation of the hydrolysis products is likely.
Both substances are water soluble and thus subject to renal elimination. Tissue accumulation can be excluded.
Executive summary:

The toxicokinetic behaviour of Di-2-EHTDG [bis(2-ethylhexyl) 2,2'-thiobisacetate] was assessed. The OECD QSAR Application Toolbox was used to make a qualitative prediction of metabolites formed in liver, skin and gastrointestinal tract.

The Danish QSAR Database was used to predict dermal and oral bioavailability of Di-2-EHTDG.

The fate of these metabolites is predicted on the basis of their chemical structure based on expert judgement.

Di-2-EHTDG is predicted to be highly bioavailable via the oral route but is very poorly absorbed via skin.

Di-2-EHTDG is expected to undergo stepwise hydrolysis of the two ester bonds yielding 2,2'-thiodiglycolic acid and 2-ethylhexan-1-ol. Both substances are water soluble and thus subject to renal elimination.

Tissue accumulation can be excluded.